Agios Pharmaceuticals (NASDAQ:AGIO) Given New $39.00 Price Target at Truist Financial

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target decreased by Truist Financial from $41.00 to $39.00 in a report released on Friday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on AGIO. HC Wainwright upped their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday. Royal Bank Of Canada raised their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Citigroup boosted their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday. JPMorgan Chase & Co. lowered their price target on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Finally, Bank of America increased their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $40.88.

Agios Pharmaceuticals Stock Down 8.3%

Agios Pharmaceuticals stock opened at $30.02 on Friday. The stock has a 50-day simple moving average of $34.48 and a 200 day simple moving average of $30.88. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -4.28 and a beta of 0.54. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 34.40% and a negative net margin of 418.24%.The firm had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. As a group, sell-side analysts anticipate that Agios Pharmaceuticals will post -6.33 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth about $25,000. Assetmark Inc. lifted its holdings in shares of Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 362 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter valued at about $40,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $49,000. Finally, Eurizon Capital SGR S.p.A. acquired a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $72,000.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue from mitapivat products Pyrukynd and Aqvesme rose to $44.7 million from $12.5 million a year earlier, helped by Aqvesme’s U.S. launch in thalassemia. The company reported 442 cumulative prescriptions as of June 30. Agios second-quarter financial results
• Positive Sentiment: Agios reported a narrower quarterly loss than the Zacks consensus estimate, while management highlighted continued development of its hematology pipeline. The company also has $964.8 million in cash, cash equivalents and marketable securities to fund commercialization and research programs. Agios Q2 earnings report
• Positive Sentiment: The FDA granted priority review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 decision date. Approval could expand the drug’s addressable market. Agios also expects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle cell review
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $55 price objective while slightly raising its long-term 2030 EPS forecast. The forecast change supports the longer-term outlook but has limited immediate impact. Agios analyst estimates
• Negative Sentiment: Agios remains deeply unprofitable. Its reported quarterly loss of $1.69 per share was slightly worse than one analyst consensus estimate of $1.65, underscoring continued earnings risk despite revenue growth. Agios earnings results
• Negative Sentiment: Truist lowered its price target from $41 to $39, although it retained a Buy rating. Separately, Pomerantz announced an investigation into potential investor claims, creating an additional headline and legal overhang. Truist price target update

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.